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Abstract
Objective:
To describe basal insulin analogue dosing irregularities, the effect of these events on patient functioning,
well-being and diabetes management, and the identification of patients most at risk.
Research design and methods:
The GAPP2 (Global Attitude of Patients and Physicians 2) study was an online multinational cross-sectional
study of patients with type 2 diabetes currently treated with basal insulin, and healthcare professionals
(HCPs) involved in the care of such patients. Basal insulin adherence patterns were evaluated with respect to
three types of dosing irregularity: missed, mistimed [2 hours from prescribed time], and reduced dose
over the last 30 days.
Results:
A total of 3042 patients treated with basal insulin analogues and 1222 prescribers completed the full survey;
38% of patients reported any type of basal insulin dosing irregularity in the last 30 days. Patients reported
missing (22% on 3 0.16 occasions), mistiming (24% on 4.2 0.21 occasions) or reducing (14% on
4.2 0.24 occasions) basal insulin doses, with 15% of patients reporting multiple types of dosing
irregularities. For most patients, missed (83%) and mistimed doses (82%) were unintentional, whereas
the majority (87%) of patients reducing doses did so intentionally. Patients who intentionally missed or
reduced a dose of basal insulin were significantly more likely to have performed this dosing irregularity on
multiple occasions. Fifty-three percent of patients increased the frequency of blood glucose monitoring, and
17% of patients extended the duration of more frequent blood glucose monitoring by one or more days as a
result of unintentional missed doses. Reduced dosing was highest in a subset of patients reporting self-
treated hypoglycaemia.
Conclusions:
Basal insulin dosing irregularities including missed, mistimed and reduced doses are common. A significant
proportion of patients also report undertaking these irregular dosing behaviours at a frequency that would be
considered by prescribers to negatively impact diabetes management. This is despite the potential under-
reporting due to recall or social bias that may be a limitation of a self-reported survey around these
behaviours.
Introduction
Non-adherence to insulin treatment is one of the most important and poorly
understood challenges that continue to impede optimal management of diabe-
tes1. The consequences of poor treatment and medication adherence are only
now being fully appreciated, with independent effects not just limited to gly-
caemic control, hypoglycaemia and health costs, but also all-cause mortality2–6.
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Insulin non-adherence has been reported in up to
two-thirds of patients6–11, with approximately one-third
reporting an average of three episodes of insulin omis-
sion/non-adherence within the previous month11.
Regimen complexity, in terms of the number of the treat-
ments and frequency of administration, is known to have
a negative impact on adherence6,7,12, as have treatment
tolerability issues13.
Hypoglycaemia has been one of the principle limita-
tions to insulin treatment2. Self-treated (minor) hypogly-
caemia has been shown to have serious implications for
patient health, psychological well-being, and adherence
to treatment regimens14–16. Ensuing fear of hypoglycae-
mia, which is increased in patients experiencing self-
treated hypoglycaemia, also negatively influences patient
self-management – patients prioritising the immediate
avoidance of hypoglycaemia (intentionally missed or
reduced doses of insulin)14 over long-term glycaemic con-
trol and prevention of complications. Conversely,
increased medication possession ratios (MPR) – a proxy
for improved treatment adherence – have been shown
to reduce hypoglycaemia incidence and healthcare
costs17–19. Further, while physicians are generally aware
of the problems of insulin specific non-adherence11,20,
data guiding the identification of non-adherent patients
and understanding of non-adherent behaviour is limited.
The objective of the current study was therefore
to describe basal insulin analogue adherence pattern,
specifically missed, mistimed and reduced doses, and the
burden of these events on patient functioning, well-being
and diabetes management; examine the relationship of
dosing irregularities with hypoglycaemia; and to examine
the influence of patient demography, behaviour, treat-
ment, and disease characteristics on the incidence of
these dosing irregularities in order to identify a clinically
relevant profile of patients most at risk for these
behaviours.
Methods
The GAPP2 (Global Attitudes of Patients and
Physicians 2) study was an online multinational cross-
sectional study of insulin treated patients with T2DM,
and healthcare professionals (primary care practitioners,
specialists and nurses) involved in the care of such
patients. The survey was conducted in United States,
Japan, United Kingdom, Germany, Canada and Denmark.
Approval for the study protocol was obtained from the
New England Institutional Review Board (document
number 12-027).
Study design
The items included in the questionnaires were developed
from multiple sources including an international steering
committee of clinical diabetes experts, current literature
on dosing irregularities and self-treated hypoglycaemia,
and from nine previously conducted patient focus groups
and interviews involving diabetes patients which were also
used to ensure high survey content validity.
The questionnaire was evaluated in two phases prior to
distribution. In the first phase, a small sample of pre-
recruitment responders completed the prototype question-
naire within each of the participating countries, in the
presence of a native speaking researcher. The researcher
was present to record any confusion arising during the
survey and did not otherwise interact with the responder.
This process of cognitive debriefing was used to finalise the
language prior to phase 2. Following cognitive debriefing
minor edits, which did not specifically affect the questions
asked, were implemented, for example the addition of
don’t know/can’t remember as a response option. No ques-
tions were removed or significantly altered. In the second
phase a small sample (50–100 responders per country)
were recruited to participate in the survey. The initial 10
responses from each country were collected and the data
and survey mechanism was analysed for sense and logic.
The survey was then extended to the full panel of patients
and healthcare professionals.
The patient 90-item questionnaire and healthcare pro-
fessional 58-item questionnaire were both structured in the
same way to facilitate subsequent comparison between
the two responder groups. Both self-complete surveys
employed an adaptive question approach to shorten com-
pletion time and minimise responder exposure to redun-
dant questions based on previous responses. Where
possible, a ‘don’t know’ was offered as an option so as to
avoid forcing responders to make inaccurate judgments.
Electronic data logic was performed during the conduction
of the survey to ensure that responders did not provide
contradictory answers to questions. Data identified as
being incomplete (defined as responses that did not
reach the end of the survey) was collected but not included
in the final analysis.
The definition of self-treated hypoglycaemia was simi-
lar in both surveys. In the patient survey, self-treated hypo-
glycaemia was defined as ‘symptoms of low blood sugar
such as sweating, weakness, trembling, and difficulty con-
centrating, which you could treat yourself (for example, by
drinking a glass of juice or taking a ‘‘sugar pill’’)’. In the
healthcare professional survey, self-treated hypoglycaemia
was defined as ‘low blood sugar events that the patients can
treat themselves, i.e. without medical assistance’. To min-
imise the impact of recall bias, reporting of self-treated
hypoglycaemia and dosing irregularities were restricted
to the 30 days prior to the completion of the survey.
These basal dosing irregularities included reduced, mis-
timed [ 2 hours from prescribed time in the respondents’
judgment] and missed doses. Dose increases were not
investigated. Basal insulin analogues were distinguished
Current Medical Research & Opinion Volume 28, Number 12 December 2012
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from insulin non-analogue preparations in the patient
questionnaire on the basis of their appearance (i.e. clear
versus cloudy). Data on specific basal insulin products used
by respondents was not collected.
When asked about their intentional basal dosing alter-
ations, patients were offered the option of saying that they
had been advised to alter their regimen by a healthcare
professional. However, when listing other reasons for
intentional dosing changes they were not specifically
asked if this had or had not been clinically advised as the
survey was intended to capture the patient perspective
regarding their self-reported adherence behaviour.
However, it was assumed that unintentional dosing alter-
ations would be non-advised and that for intentional
dosing behaviours certain reasons (excluding advised by a
healthcare professional as documented above) would be
likely to constitute clinically advisable alterations (my
blood sugar was too low; my blood sugar was too high; I
had recently exercised; I had skipped a meal; my eating
pattern was not as it normally is) and other reasons would
not alignwith clinical recommendations (to reduce the risk
of having a low blood sugar; I ran out/was running low on
insulin; I was in a social situation where I didn’t feel com-
fortable). A response option for ‘other’ was also provided.
Participants
Patients invited to participate in the survey were recruited
from an established online general population sample
comprising 6.5 million members within the countries sur-
veyed. These panels were identified via an independent
research company (Bryter Limited) who contracted com-
mercial research panels such as Research Now, GMI/
Lightspeed and WorldOne, etc. The panels were com-
prised of a representative sample of the online population
as a whole for each country in order not to bias the sample
to any particular demographic group or respondent profile.
Members were recruited from a broad array of online and
offline approaches that best represent the local online
community as a whole within each country. Recruitment
techniques include banner placements on websites, email
campaigns, online advertising, blogs, social media, refer-
rals through existing panel members, affiliate marketing
(including TV/print) and text (SMS) mobile campaigns.
Potential patients were initially invited by email to par-
ticipate in the survey based on previous survey evidence of
diabetes and age over 40 years; invitations were then ran-
domly distributed. Inclusion criteria were as follows: diag-
nosis of type 2 diabetes made by a healthcare professional
(self-reported); age over 40 years; and current treatment
with a long-acting (basal) insulin alone or in combination
with a short-acting (bolus) insulin. Patients currently man-
aged with bolus only or premixed insulin were excluded
from the survey, as were patients using insulin pumps.
Similarly, healthcare professionals were invited from a
panel comprising over 600,000 members in the countries
surveyed. Invitations were emailed to random samples
within each professional group (primary care, diabetes spe-
cialist and nurse). Email responders were screened accord-
ing to the following study inclusion criteria: minimum
2 years post qualification, minimum of 10 patients treated
with insulin analogues per month (every 3months in Japan
and Denmark), and minimum number of patients with
type 2 diabetes seen per month; for primary care physi-
cians, the minimum number of patients was 20 (5 in
Japan and Denmark to reflect the national situation),
and for specialists the minimum number of patients was
40 (30 in Japan and 20 in Denmark).
Non-monetary incentives were offered to patients
(equivalent in value to 0.30–1.10 USD per minute) and
monetary incentives to healthcare professionals (1.60–
4.70 USD per minute), in accordance with local
regulations.
Data were stored on secure servers in compliance with
the UKData Protection Act (1998) and collected data was
stored by the research company separately from any per-
sonal or contact information. Each respondent was issued
with a unique URL, which could be used once and elec-
tronic data was de-identified with respondents identified
by study ID (RESPID) only. The data was analysed on an
aggregated level.
In this analysis, we report on the subset of type 2 dia-
betes patients treated with insulin analogues (patients),
and primary care and specialist healthcare professionals
(prescribers).
Primary variables
The primary variables of interest for characterising adher-
ence patterns in patients were: basal insulin dosing irreg-
ularities in the past 30 days (frequency of missed doses,
mistimed doses [2 hours from prescribed time in the
respondents’ judgement], or reduced doses). Dosing irreg-
ularities are only reported in basal insulin due to the fact
that bolus alterations are common and in many cases based
on clinical advice. Additionally the incidence of inten-
tional dosing irregularities and reasons for this behaviour,
and the impact of dosing irregularity on functional well-
being are reported. For physicians, the primary variable of
interest was the level of patient dosing irregularity (missed,
mistimed and reduced dose) believed to be of clinical
relevance.
Statistical analysis
Continuous data are described as mean (standard devia-
tion) in tables or mean standard error in text for normal
distributions or median (range) for skewed distributions.
Current Medical Research & Opinion Volume 28, Number 12 December 2012
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Categorical data are presented using frequencies. Outliers
were defined as values lying more than 1.5 interquartile
ranges (IQRs) below the first quartile or above the third
quartile; and in instances where outlying values exhibited
a large degree of influence on the parameter of interest (as
assessed by Cook’s distance), these values were removed
from the analysis.
Group comparisons of continuous data were made using
the unpaired t-test. Pearson’s chi squared test was
employed to compare categorical data. In all analyses,
level of significance was set at a¼ 0.05. Responses identi-
fied electronically as incomplete were excluded from the
analyses.
CHAID (Chi-squared Automatic Interaction
Detection) analysis21,22 was used to test for interactions
between variables and identify which patient factors
were most associated with three different types of basal
insulin dosing irregularity: missed dose, mistimed dose,
and reduced dose. The CHAID tree branches show the
proportion of total events (top section of the boxes) and
proportion of patients (bottom section of the boxes) with
the characteristics described by the branching variables.
Whereas logistic and linear regression models allow
assessment of the effects of multiple characteristics simul-
taneously, the CHAID analysis permits the identification
of specific subsets of the sample population reporting dis-
proportionately high frequencies of dosing irregularity.
The CHAID analysis constructs prediction trees for each
dosing irregularity, where each branch identifies a split
condition (based on a response to an explanatory variable)
to yield the statistically optimum prediction of character-
istics that identifies patients most likely to engage in the
dosing irregularity under examination. In order to con-
struct the decision tree, factors from the survey were
grouped according to four conceptual domains to provide
a structure and informed analysis framework: (1) disease
history and management (duration of diabetes, diabetes
specific co-morbidity, non-insulin antidiabetes treat-
ments, duration of insulin therapy, insulin regimen, cur-
rent method of basal insulin administration, number of
insulin injections per day, and number of visits to a health-
care professional in the last 12 months); (2) patient behav-
iours (missed, mistimed or reduced basal insulin doses in
the last 30 days; (3) patient perceptions (perceived diabe-
tes control, basal insulin inconvenience, and the extent to
which basal insulin interferes with lifestyle and activity,
patient satisfaction with current basal insulin treatment,
patient comfort with taking insulin, patient guilt or worry
about missed doses, patient downplaying or hiding missed
doses from healthcare professionals, worry about hypogly-
caemia; and (4) patient attributes (age at diagnosis, cur-
rent age, gender, BMI, current working situation,
educational level, lifestyle activity and eating meals at reg-
ular times). Bonferroni adjustment was used to correct for
multiple splits of a single predictor.
Dosing irregularities were retrospectively defined as an
ordinal outcome according to the responses from the pre-
scriber arm of the study on clinical impact: no events (0),
one to four irregularities in a 30 day period (1), or five or
more irregularities in a 30 day period (2).
All analyses were performed using the statistical pack-
age SI-CHAID (Version 4.0.4, Statistical Innovation).
Results
A total of 1,034,363 individuals (from general population
research panels) were invited to participate in the patient
survey (initial response rate 9.8%). These general popula-
tion respondents produced 13,057 eligible patients who
met the pre-specified entry criteria, of whom 3587 eligible
respondents went on to complete the full survey, response
rate 27.5% (Figure 1). Patients treated with insulin ana-
logues comprised 84.8% (n¼ 3,042) of the complete
responses received.
In the healthcare professionals group, 36,240 were
invited to participate in the survey. Out of 5115 respond-
ing to the invitation, 2667 were eligible for survey inclu-
sion, and 1653 completed all questions. Physicians
comprised 73.9% (n¼ 1222).
In the results presented only one outlier response was
removed in relation to the reported number of mistimed
doses in the last 30 days.
Demographic and treatment information for both
responder groups are summarised in Table 1.
Prevalence and incidence of dosing irregularities
A total of 38% of patients reported any type of basal insu-
lin dosing irregularity in the last 30 days. In this time
period, 22% of patients reported missing (mean 3 0.16
occasions), 24% mistiming (mean 4.2 0.21 occasions)
and 14% reducing (mean 4.2 0.24 occasions) at least
one basal insulin dose (Table 2).
Multiple dosing irregularities also occurred: 3% of
patients reported having missed, mistimed and reduced
a dose of basal insulin; 12% reported performing two out
of the three dosing irregularities, and 23% of patients
reported a single type of dosing irregularity.
Of those patients who reported dosing irregularities,
17% of patients reported missing, 27% mistiming and
27% reducing their basal insulin dose five times or more.
The frequency of missed doses, mistimed doses and reduced
doses of basal insulin were similar for patients using basal
insulin alone versus those using basal with bolus insulin
(Table 3).
Althoughmissed andmistimed doses were usually unin-
tentional (83% and 82% respectively), the majority of
patients who reduced their dose of basal insulin did so
intentionally. In the last 30 days, 87% of patients who
Current Medical Research & Opinion Volume 28, Number 12 December 2012
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had reduced their last dose of basal insulin reported that
this was intentional. Patients who intentionally missed or
reduced a dose of basal insulin on the last occasion were
more likely to have performed this dosing irregularity on
multiple occasions over the last 30 days: missed doses
(5.0 0.61 versus 2.6 0.14 occasions in patients inten-
tionally and unintentionally missing their last dose,
p50.001), reduced doses (4.3 0.27 versus 3.0 0.71
occasions in patients intentionally and unintentionally
reducing their last dose, p¼ 0.091) (Table 3). Reasons
given for intentionally missing, mistiming or reducing a
basal insulin dose include a mixture of those defined as
more likely to be in line with clinical advice and those
more likely to be contrary to healthcare professional rec-
ommendations (Figure 2). The proportions of the reported
reasons for intentional adjustments assumed to be contrary
to clinical advice based on our definitions were 36%
for missed doses, 28% for mistimed doses and 34% for
reduced doses.
Effect of dosing irregularities on diabetes
management
Patients who had unintentionally missed doses reported
changes to diabetes management and well-being: 53% of
patients increased the frequency of blood glucose monitor-
ing, and 17% of patients extended the duration of more
frequent blood glucose monitoring by one or more days;
69% of patients reported being ‘more careful with their
diabetes management’ (28% for a few days or more).
When asked, 39% of all patients said they would worry
about missing the occasional basal insulin dose; and 37%
would feel guilty about an unintentional omission.
Physicians reported that the frequency of basal insulin
dosing irregularities in the last 30 days that they perceived
to have a significant impact on glucose control was
4.3 0.1 missed, 5.7 0.2 mistimed, or 5.1 0.1 reduced
basal insulin doses for patients treated with a basal insulin
regimen; and 4.3 0.1 missed, 5.6 0.2 mistimed and
4.8 0.1 reduced basal insulin doses for patients on
basal–bolus regimens. Despite acknowledgement of the
clinical relevance of irregular dosing, 32% of physicians
reported not routinely discussing basal insulin dosing irreg-
ularities with their basal insulin patients and 29% did not
routinely discuss them with their basal–bolus patients.
Effect of dosing irregularities on patient
functioning
Being required to administer basal insulin at the same pre-
scribed time every day was also reported by patients as
having a negative impact on one of several activities in
47% of patients (Figure 3). The negative impact was high-
est for spontaneous activities such as the ability to stay
1,070,603 invitations
sent to participate in 
the survey
36,240 HCPs invited
5,115 HCPs responded
2,667 HPCs entered
the survey
1,653 complete HCP
responses received
1,222 complete
primary care and
specialist responses
received
431 completed 
diabetes nurses 
and educator 
responses received
1,014 incomplete
HCP responses
received
(not analysed)
2,448 HCPs
screened out
31,305 HCPs did 
not respond
1,034,363 sample of 
general population
invited 
101,499 sample of 
general population
responded
13,057 patients
entered the survey
3,587 complete 
patient responses
received
3,042 complete insulin
analogue patient
responses received
545 complete NPH
insulin patient
responses received
9,470 incomplete
patient responses
received 
(not analysed)
88,392 sample of 
general population
screened out
932,864 sample of 
general population
did not respond
Figure 1. Patient and healthcare professional survey recruitment flow diagram.
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overnight without planning (33%), and the ability to go
on holiday or to travel (26%).
Patient characteristics associated with dosing
irregularities (CHAID analysis)
For missed dosing, the report of a mistimed dose in the
preceding 30 days was identified as the variable most indi-
vidually associated with an increased risk of missed doses
and was therefore the primary differentiator in the CHAID
tree (Figure 4a). Eating meals at regular times was identi-
fied as the key secondary differentiating variable. For those
who had not reported a mistimed dose they were only at an
increased risk of reporting a missed dose if they also had
irregular mealtimes and had a poor perception of their
diabetes control. By contrast, patients who had mistimed
a dose in the last 30 days were at increased risk if they did
not have regular meals. Additionally if patients had mis-
timed a dose and did eat regular meals, they were still at
increased risk if they were anxious about co-morbidities; or
if they were not anxious and female; or if they were not
anxious, were male and were also un-satisfied with their
insulin treatment. The characteristics of the patients most
at risk of reporting missed doses (defined by the ratio of the
proportion of reported missed doses to the population pro-
portion) were those who mistimed a dose, never/rarely ate
meals at regular times and were overweight or obese. This
group of patients represented 2.6% of the patient sample
but accounted for 17.1% of all reported missed doses.
For the mistimed dosing CHAID tree (Figure 4b), the
report of a missed dose in the preceding 30 days was iden-
tified as the variable most individually associated with
increased risk of mistimed doses. Eating meals at regular
times and basal insulin convenience were identified as the
key secondary differentiating variables. For those who had
not reported a missed dose they were only at an increased
risk of mistimed doses if they never/rarely or sometimes ate
meals at regular times, and had a poor perception of their
diabetes control; or they had a moderate perception of
diabetes control in combination with administering their
basal insulin by a vial and having a barely active lifestyle.
For patients reporting missed doses in the preceding 30
days, they were at increased risk of mistiming doses if
they also reported that basal insulin was inconvenient.
Table 1. Patient and physician demographics.
TOTAL US Canada Japan UK Denmark Germany
PATIENT DEMOGRAPHICS
Base (n) 3042 1850 156 355 322 57 302
Age (years) 61 (8.12) 62 (7.63) 60 (8.26) 57 (8.12) 60 (8.63) 62 (8.27) 57 (7.75)
Male (%) 59 50 54 85 67 65 70
Duration of diabetes (years) 11 (6.70) 12 (6.56) 12 (8.05) 10 (6.87) 11 (6.45) 11.7 (6.47) 9 (5.94)
Duration of insulin
treatment (years)
5 (4.44) 5 (4.46) 5 (4.92) 5 (4.28) 5 (4.28) 7 (5.80) 5 (4.03)
Insulin treatment (%)
Basal only 48 51 50 43 52 51 33
Basal–bolus 52 49 50 57 48 49 67
Number of basal injections per day 1.3 (1.21) 1.3 (1.04) 1.3 (0.57) 1.3 (0.75) 1.3 (0.69) 1.4 (0.77) 1.7 (2.60)
Perceptions of control (%)
Poor 10 10 7 21 6 4 5
Moderate 56 58 54 64 53 39 39
Good 34 32 38 15 41 58 56
BMI (kg/m2) 34 (19.22) 36 (19.37) 38 (30.75) 26 (13.71) 32 (17.84) 35 (33.89) 32 (7.42)
Number of diabetes complications*,
median (range)
2 (0–13) 2 (0–10) 2 (0–11) 1 (0–13) 3 (0–10) 3 (0–8) 3 (0–9)
Education (%)
Some high school 3 1 1 2 14 5 5
High school graduate 23 21 14 32 22 14 32
Some college (no degree) 23 29 17 17 12 5 8
College (degree) 37 35 34 49 43 63 36
Masters/PhD/Postdoctorate 13 14 34 0 7 6 17
PHYSICIAN DEMOGRAPHICS
Base (n) 1222 311 202 222 208 70 209
Specialty (%)
Primary care 55 51 79 40 50 73 51
Specialist 45 49 21 60 50 27 49
Time since qualified (years) 17 (8.17) 17 (7.66) 21 (8.46) 16 (8.54) 14 (7.27) 18 (9.39) 14 (6.32)
Average number of insulin treated patients with T2DM aged 40þ
Primary care 67 (63.42) 89 (67.44) 80 (73.29) 27 (21.30) 70 (60.30) 26 (15.93) 73 (59.91)
Specialist 147(112.02) 165 (101.48) 130 (81.01) 113 (125.68) 130 (89.05) 69 (28.87) 197 (126.41)
*Out of a total of 13 listed complications. Continuous variables are given as mean (standard deviation) unless specified.
BMI: body mass index; T2DM: type 2 diabetes mellitus.
Current Medical Research & Opinion Volume 28, Number 12 December 2012
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If they had missed a dose but did not think that basal
insulin was inconvenient, they remained at increased
risk if they had reduced a dose of their basal insulin; or if
they had not reduced a dose but had thought they had poor
or moderate diabetes control. The patient sub-set most at
risk of mistimed doses (accounting for 17% of mistimed
doses) were those patients who perceived basal insulin
dosing to be inconvenient and reported missed doses
(4% of the total patient sample).
For reduced dosing, the primary variable identified in
the CHAID tree (Figure 4c), i.e. the variable most indi-
vidually associated with an increased risk of reduced doses,
was self-treated hypoglycaemia in the preceding 30 days.
Mistiming a dose was identified as the key secondary
differentiating variable. For those who had not experi-
enced a self-treated hypoglycaemic event the only groups
more associated with reduced doses were those aged 50
years and over and those aged 40–49 years who had also
been on insulin for more than 2 years and who had also
missed a dose. For those reporting self-treated hypoglycae-
mia, those patients who had mistimed a dose and did not
feel guilty about missed doses were at increased risk of
reducing doses. Additionally, for those reporting self-trea-
ted hypoglycaemia that had not mistimed a dose were at
increased risk of reporting reduced doses if they adminis-
tered their insulin by a pen; or if they did not use a pen but
also reported nerve damage. The subset of patients with
the highest risk of reduced dosing was those with a history
Table 3. Basal insulin dosing irregularities in the previous 30 days, by insulin regimen and patient intention.
Dosing irregularities by insulin regimen Basal insulin Dosing irregularities by patient intention
Basal insulin
only
Basal and
bolus insulin
p value Intentionally dose
irregularly last
time they did this
Did not intentionally
dose irregularly last
time they did this
p value
MISSED A DOSE OF BASAL INSULIN
Effective base (n) 1399 1484 178 1176
Proportion of patients (%) 24% (329) 21% (318) 0.179 63% (112) 45% (527) 50.001
Mean number of missed doses 2.9 (3.39) 3.2 (4.61) 0.347 5.0 (6.47) 2.6 (3.14) 50.001
5þ times in past 30 days (%) 3.7% (52) 3.7% (55) 0.987 17.4% (31) 6.3% (74) 50.001
MISTIMED A DOSE OF BASAL INSULIN
Effective base (n) 1338 1403 237 1097
Proportion of patients (%) 26% (353) 22% (303) 0.003 50% (119) 46% (509) 0.286
Mean number of mistimed doses 4.2 (5.03) 4.3 (5.83) 0.816 4.8 (5.22) 4.1 (5.33) 0.191
5þ times in past 30 days (%) 7.3% (98) 5.6% (79) 50.071 16.9% (40) 12.1% (133) 0.048
REDUCED A DOSE OF BASAL INSULIN
Effective base (n) 1405 1508 856 207
Proportion of patients (%) 14% (197) 15% (220) 0.662 43% (364) 21% (44) 50.001
Mean number of reduced doses 4.2 (4.91) 4.2 (5.09) 1 4.3 (5.07) 3.0 (4.69) 0.091
5þ times in past 30 days (%) 3.6% (51) 4.0% (60) 0.623 12.0% (103) 2.9% (6) 50.001
Continuous variables are given as mean (standard deviation) unless specified.
Table 2. Basal insulin dosing irregularities in the previous 30 days.
Global USA Canada Japan UK Denmark Germany
MISSED A DOSE OF BASAL INSULIN
Effective base (n) 2883 1754 151 334 315 57 272
Proportion of patients (%) 22% (647) 26% (455) 23% (34) 15% (49) 16% (51) 12% (7) 19% (51)
Mean number of missed doses 3 (4.04) 3.2 (4.20) 3.2 (5.42) 3.1 (4.51) 2.1 (2.18) 1.1* (0.38) 2.3 (2.11)
5þ times in past 30 days (%)* 3.7% (107) 4.7%% (82) 2.6% (4) 3.0% (10) 1.6% (5) 0% (–) 2.2% (6)
MISTIMED A DOSE OF BASAL INSULIN
Effective base (n) 2741 1650 148 334 305 50 254
Proportion of patients (%) 24% (656) 26% (423) 26% (38) 18% (60) 20% (62) 20% (10) 25% (63)
Mean number of mistimed doses 4.2 (5.41) 4.2 (5.30) 4.8 (6.25) 5.4 (5.46) 3.7 (4.70) 3.7* (3.59) 3.9 (6.38)
5þ times in past 30 days (%)* 6.5% (177) 6.5% (108) 6.8% (10) 8.1% (27) 4.3% (13) 6.0% (3) 6.3% (16)
REDUCED A DOSE OF BASAL INSULIN
Effective base (n) 2913 1792 152 345 312 51 261
Proportion of patients (%) 14% (417) 15% (260) 13% (19) 11% (37) 18% (56) 12%(6) 15% (39)
Mean number of reduced doses 4.2 (5.00) 4.3 (5.19) 2.8* (2.32) 3.8 (2.98) 3.8 (5.15) 1.3* (0.52) 5.3 (6.05)
5þ times in past 30 days (%)* 3.8% (111) 4.0% (72) 2.0% (3) 3.5% (12) 3.5% (11) 0% (–) 5.0% (13)
Continuous variables are given as mean (standard deviation) unless specified.
*Small base size.
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of self-treated hypoglycaemia, mistimed doses, did not feel
guilty about missing the occasional basal insulin dose and
were aged 50 and over. This high risk group comprised of
2.3% of the sample but accounted for 10% of reduced
dosing events.
Taking into account the three CHAID analyses and the
characteristics entered into them for basal dosing
irregularities, the profile of patients who are at increased
risk of missed/mistimed or reduced doses show some key
attributes some of which are common across the individual
irregularities. These factors may act as simple and useful
indicators for clinical practice to aid the identification of
patients who dose irregularly. These include reports of at
least one dosing irregularity (those that report one type of
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Figure 2. The five most common reasons for intentional dosing irregularities.
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irregularity are often at increased risk of reporting
another), poor perceived diabetes control, irregular meal-
times, the perception that basal insulin is inconvenient
and self-treated hypoglycaemia.
Discussion
This is the first time that intentional non-adherent dosing
behaviour has been shown to be associated with episodes of
self-treated hypoglycaemia. This large multinational cross-
sectional survey shows that more than a third of patients
report one or more basal insulin analogue dosing irregular-
ities comprising missed, mistimed or reduced doses. These
dosing irregularities were usually unintentional; in con-
trast, reducing doses of the basal insulin analogue was
performed intentionally by over four fifths of patients
reporting this type of dosing irregularity often for clinically
inadvisable reasons. Furthermore, a substantial proportion
of patients reported a frequency of dosing irregularities at a
level that physicians perceived would have a negative
impact on diabetes management. Despite the prevalence
of dosing irregularities, however, 32% of prescribers did
not routinely discuss these basal adherence patterns with
their basal only patients (29% with their basal–bolus
patients). Considering these results in the context of the
wider type 2 diabetes population suggests that there is a
sub-population of insulin analogue users who repeatedly
dose irregularly at a level which has the potential to
affect glucose control and long-term outcomes23.
There appears to be good agreement with the adherence
patterns, in this case basal dosing irregularities, reported in
this study, and those previously reported in the literature.
In a mixed population of patients with type 1 and type 2
 Negatively Affected 
Your relationship with your partner
      Your night time routine
      Your ability to socialise freely
      Your ability to be spontaneous and change your plans
      Taking part in sport and exercise
      Attending work
      Performing at your best at work
      Going on holiday or travelling
      Your ability to commit to future events
      Your ability to stay away overnight without planning in advance
Your usual daily routine (i.e. getting dressed, cleaning your teeth etc.)
      Your ability to run errands
      Dining out
      Your ability to focus and concentrate
      Scheduling your day
8%
15%
16%
25%
13%
9%
9%
26%
15%
33%
8%
11%
18%
9%
12%
Proportion of patients negatively affected
Figure 3. The effect of having to take basal insulin at the prescribed time every day on patient well-being and functioning.
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diabetes, intentional insulin omission was reported by
more than half of respondents, with 20% of respondents
reporting regular omission over an undefined time inter-
val24. In a more recent survey, one third of patients with
type 1 and type 2 diabetes reported insulin omission/non-
adherence on an average of 3.3 days within the previous
month11. Although these studies did not evaluate the
effect of missed, mistimed and reduced basal insulin
dosing specifically, non-adherence to insulin has been
shown to be associated with worse glycaemic con-
trol6,7,10,25–27 and mortality5.
Treatment adherence is also commonly assessed
through use of the MPR, the ratio of days’ medication is
supplied over a defined time interval. The MPR for insulin
use in patients with type 2 diabetes has previously been
reported to be within the range of 58–77%6,7,27,28.
(b)
(a)
Figure 4. The CHAID tree showing combinations of patient characteristics that are associated with increased risk of (a) missed, (b) mistimed; and (c) reduced
doses of basal insulin within the previous 30 days.
Current Medical Research & Opinion Volume 28, Number 12 December 2012
10 T2DM adherence patterns: missed, mistimed and reduced doses Brod et al. www.cmrojournal.com ! 2012 Informa UK Ltd
Cu
rr 
M
ed
 R
es
 O
pi
n 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
N
ov
o 
N
or
di
sk
 A
/S
 o
n 
11
/1
5/
12
Fo
r p
er
so
na
l u
se
 o
nl
y.
However, despite the non-adherence levels recorded by
MPR and the frequency of their use, the measure is
likely to include some element of insulin wastage, would
not be able to detect mistimed doses and would also be
unable to differentiate between missed doses and reduced
doses. Interestingly, while the three different dosing irreg-
ularities reported appear to be closely interlinked they are
nevertheless unique behavioural entities and should be
measured as such. In particular, although missed and mis-
timed doses were clearly associated with each other and
poor self-perception of diabetes control; missed doses were
more clearly associated with whether or not patients ate
meals at regular times, whereas mistimed doses were more
strongly associated with perceived insulin inconvenience.
These findings add further evidence that self-treated
hypoglycaemia can result in prolonged periods of detri-
mental self-management behaviour14,29,30, particularly in
a sub-group of patients such as those who proactively alter
their regimen to reduce hypoglycaemic risk. Previously
published studies have reported that patients required an
average of 5.6 extra blood glucose test strips in the week
following a non-severe hypoglycaemic event, and that
25% of patients reduced the dose of insulin16. The causal-
ity of the association between reduced dosing and self-
treated hypoglycaemia cannot be determined from the
cross-section survey data available. However, when asked
about the reasons behind intentional dosing regularities
the two most frequently reported reasons were low blood
sugar and hypoglycaemia risk reduction (Figure 2), i.e. rea-
sons that relate to both pre- and post-hypoglycaemia alter-
ations. Indeed, this association between self-treated
hypoglycaemia and reduced dosing may well explain the
lower MPRs reported with insulin compared to oral agents
and GLP-1 analogues7,28 – with some insulin treated
patients reducing doses of prescribed insulin in an attempt
to mitigate more frequent episodes of hypoglycaemia by
maintaining a higher blood glucose level, as has been
noted in previous studies31,32. Interestingly, Donnelly
et al.6 reported a tendency for poorly adherent patients
to be prescribed larger quantities of insulin, perhaps in
an attempt to improve glycaemic control in the context
of poor adherence. The present study suggests that in addi-
tion to some inappropriate dosing behaviour on the part of
the patient, there may also be an inappropriate response by
the physician (increasing prescribed dose) that would fail
to address the underlying issue of non-adherence (i.e.
intentional pre-hypoglycaemia dose reduction by the
patient).
Previously reported risk factors for insulin omission/
non-adherence include male gender, younger age, more
frequent hypoglycaemia, those who regarded insulin
adherence as less important, as well as those who were
(c)
Figure 4. Continued.
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more concerned about perceived lifestyle changes, dissat-
isfaction with the inflexibility of the injection regimen,
interference of injection with daily patient activities and
causing the patient embarrassment33. Other authors have
similarly reported associations of poor adherence with
patients being professionally active (currently working),
not feeling confident about the future, and lack of family
and social support9. Notably, patients tend to be signifi-
cantly less satisfied with insulin treatment than physi-
cians11. The present study goes one step further in
identifying specific subsets of patients based on demo-
graphic, disease, treatment and behavioural variables –
all of which are consistent with the literature. The present
study showed that overweight patients with irregular meal
times were most at risk of missing doses, and that patients
who perceived basal insulin to be inconvenient were most
likely to have mistimed doses. These patient characteris-
tics could be easily identified during clinical consultations,
and would alert the physician to possible insulin dosing
irregularities and the potential need to re-educate patients
or introduce other counter-measures. The finding of an
association between self-treated hypoglycaemia and
reduced dosing also reinforces the need for healthcare pro-
viders to carefully evaluate patients’ history of hypoglycae-
mia, and to try to identify antecedents and recommend
appropriate changes to treatment.
As the consequences of irregular dosing are likely to
increase in patients reporting multiple types or high fre-
quencies of dosing irregularities, these would be expected
to benefit from targeted diabetes management interven-
tions. Particularly, those who intentionally alter their insu-
lin dosing, as our analysis shows that they undertake these
behaviours on a more regular basis than those who do not.
The present study also shows that, although patients may
recognise the potential implications of missed doses for the
management of their diabetes, they remain unable to
adhere to strict treatment regimens, and adhering to
these strict regimens also negatively impacted patients’
functional and emotional well-being.
However, there are several limitations to the study. As
has been discussed, this is a cross-sectional study, which
means that we are unable to attribute a causal effect
between any of the associations reported, or determine
in which sequence the reported associations occurred. In
addition, the sample of respondents was non-randomised
although they were targeted via general population
research panels and not through patient specific channels
in an attempt to minimise some elements of selection bias.
This recruitment methodology, however, led to an initial
response rate that may be perceived as low but was in line
with initial estimations used as part of the sample size
calculations and the complete response rate among those
eligible was 27.4%. Additionally, the CHAID analysis
undertaken is a multivariate technique which also helps
to mitigate the effect of other recorded respondent
variables, although the potential role of unidentified con-
founders still cannot be excluded.
As the survey was focused on insulin analogue users the
results of the survey may not be generalisable to patients
using other insulin preparations, and though the survey
sought to include countries with different cultural and
ethnic backgrounds the largest groups of respondents
were from Western countries. In addition, the survey was
conducted online, which may have led to an over-repre-
sentation of some key responder groups, for example: youn-
ger age group, those in employment and those living in
non-isolated situations. Differences in online penetration
in the participating countries may also be a potential con-
founder. At present, the effect of ethnicity and cultural
factors on adherence remains poorly understood34,35.
It is also likely that the reported basal dosing irregular-
ities are underestimated as the patient survey was self-com-
pleted and reports were based on patient judgement which
may have led to incorrect classifications. Additionally,
recall bias and social bias may also have lead to an under-
estimation of dosing irregularities particularly given that
dosing irregularities may be perceived as potentially inap-
propriate medication taking behaviour. Social bias may
also have played a role in some of the prescriber data
reported, particularly in relation to the subjective report-
ing of the frequency of discussion of dosing irregularities in
consultation. In this case it should also be noted that the
depth of conversation around these issues reported was not
further investigated. However, given that the research
panels were recruited to be representative of the online
community; the online penetration in the surveyed coun-
tries was judged to be broadly in line prior to initiation;
dosing irregularity definitions were always provided in the
questionnaires and that both patients and prescribers were
informed that results were confidential and that data is
only presented in these analyses focusing on a 30 day
period, these biases may have had limited effect.
Yet, despite these findings, future research is required
which should focus on interventions that address both the
reasons for regular and intentional basal insulin dosing
irregularities highlighted in this study, and establishing
causality between basal dosing adherence patterns and
self-treated hypoglycaemia.
Conclusion
Basal insulin dosing irregularities including missed, mis-
timed and reduced doses are common in patients using
insulin analogue regimens, and a significant proportion
of patients undertake irregular dosing behaviour at a fre-
quency that would be considered by prescribers to nega-
tively impact diabetes management. Clinicians should
focus on identifying patients with a higher likelihood of
dosing irregularities including those that report self-treated
Current Medical Research & Opinion Volume 28, Number 12 December 2012
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hypoglycaemia (most highly associated with reduced
doses), not having regular mealtimes and poor self-percep-
tion of their diabetes control (missed and mistimed doses).
Patient concerns about lifestyle interference and insulin
treatment burden related to fixed administration times
should also be taken into consideration. The results add
to a growing body of evidence supporting continued efforts
to refine insulin therapy and treatment regimens in terms
of safety, simplicity and convenience.
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